Mouse CXCL17/VCC‑1 Antibody

CXCL17, also known as dendritic cell and monocyte chemokine-like protein (DMC) and VEGF-correlated chemokine-1 (VCC-1), is a secreted molecule with a size and predicted three-dimensional folding pattern similar to that of chemokines CXCL8/IL-8 and CXCL14/BRAK (1, 2). It has no predicted N-glycosylation sites, so cleavage of a 22 amino acid (aa) signal sequence likely results in a mature mouse CXCL17 molecule of 97 aa and 11 kDa size. CXCL17 is constitutively produced by airway and intestinal epithelium (1). It induces the chemotaxis of quiescent, but not LPS‑activated peripheral blood monocytes and dendritic cells, and also binds these cells specifically (1). CXCL17 expression is increased in endothelial cells when they are induced to form tubes in vitro (2). Transgenic overexpression in NIH3T3 cells causes upregulation of proteins such as VEGF and FGF basic, and increases cell growth rate and tumorigenicity (2). CXCL17 and two other chemokines that play roles in angiogenesis, CXCL1/GRO and CXCL8/IL-8, show significantly correlated expression with that of VEGF in primary lung, breast and esophageal tumors (2). CXCL17 is therefore suggested to play a role in tumor angiogenesis. Mature mouse CXCL17 shares 82%, 71% and 66% amino acid sequence identity with rat, human and bovine CXCL17, respectively.